Saxagliptin Plus Metformin Lowers HbA1C Levels Over Metformin Alone In Phase III Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Data involving 743 patients is the first Phase III data evaluating the DDP-4 inhibitor to be released by Bristol/AstraZeneca.
You may also be interested in...
Bristol/AstraZeneca Demonstrate Safety In Dapagliflozin Study For Type 2 Diabetes
Companies report Phase IIa data evaluating the sodium-glucose transporter 2 inhibitor at American Diabetes Association meeting.
Bristol/AstraZeneca Demonstrate Safety In Dapagliflozin Study For Type 2 Diabetes
Companies report Phase IIa data evaluating the sodium-glucose transporter 2 inhibitor at American Diabetes Association meeting.
Janumet Approved; Type 2 Diabetes Therapy Will Be Available By End Of April
Price for the Januvia/metformin combo will be the same as for Januvia alone, Merck tells “The Pink Sheet” DAILY.